Sonia Franciosi

List of Publications by Year
in descending order

32	836	623734 14	501196 28
papers	citations	h-index	g-index

33	33	33	1416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiology, 2022, 7, 84.	6.1	28
2	An International Multicenter Cohort Study on Î²-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
3	Sudden Cardiac Arrest in the Paediatric Population. , 2022, 1, 45-59.		1
4	Potential Role of Life Stress in Unexplained Sudden Cardiac Arrest. CJC Open, 2021, 3, 285-291.	1.5	7
5	Paediatric supraventricular tachycardia patients potentially more at risk of developing psychological difficulties compared to healthy peers. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1017-1024.	1.5	1
6	Potential overdiagnosis of long QT syndrome using exercise stress and QT stand testing in children and adolescents with a low probability of disease. Journal of Cardiovascular Electrophysiology, 2021, 32, 500-506.	1.7	10
7	Intermediate-coupled premature ventricular complexes and ventricular tachycardia during exercise recovery. HeartRhythm Case Reports, 2021, 7, 127-130.	0.4	3
8	Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2021, 7, 437-441.	3.2	18
9	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2021, 18, 1825-1832.	0.7	13
10	Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist. International Journal of Molecular Sciences, 2021, 22, 9293.	4.1	7
11	Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease. Npj Aging and Mechanisms of Disease, 2021, 7, 26.	4.5	8
12	Initially unexplained cardiac arrest in children and adolescents: A national experience from the Canadian Pediatric Heart Rhythm Network. Heart Rhythm, 2020, 17, 975-981.	0.7	21
13	Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 2019, 30, 1923-1929.	1.7	11
14	The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. Journal of Community Genetics, 2018, 9, 257-262.	1.2	5
15	Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications, 2018, 6, 16.	5.2	47
16	Dynamic Electrocardiographic Abnormalities Captured in TimothyÂSyndrome. JACC: Clinical Electrophysiology, 2018, 4, 1486-1487.	3.2	0
17	Polymorphic ventricular tachycardia associated with an episode of reflex syncope: Is this the needle in the haystack?. HeartRhythm Case Reports, 2018, 4, 510-513.	0.4	2
18	SCN5A mutations in 442 neonates and children: genotypeâ€“phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	2.2	33

#	Article	IF	Citations
19	The role of the autonomic nervous system in arrhythmias and sudden cardiac death. Autonomic Neuroscience: Basic and Clinical, 2017, 205, 1-11.	2.8	104
20	The Safety and Effectiveness of Flecainide in Children in the Current Era. Pediatric Cardiology, 2017, 38, 1633-1638.	1.3	14
21	p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntingtonâ€™s disease. Neuroscience, 2017, 352, 79-87.	2.3	3
22	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports, 2016, 6, 31652.	3.3	59
23	L8â€…Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A92.3-A93.	1.9	0
24	Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biology, 2016, 14, 108.	3.8	22
25	Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease, 2015, 76, 24-36.	4.4	48
26	Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2015, 76, 46-56.	4.4	78
27	A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics, 2015, 24, 2604-2614.	2.9	48
28	A systematic review and metaâ€analysis of clinical variables used in Huntington disease research. Movement Disorders, 2013, 28, 1987-1994.	3.9	8
29	Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nature Communications, 2013, 4, 2906.	12.8	15
30	Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease, 2012, 1, 243-260.	1.9	7
31	Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 45, 438-449.	4.4	105
32	IL-8 enhancement of amyloid-beta (AÎ²1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. Journal of Neuroimmunology, 2005, 159, 66-74.	2.3	82